Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

Marta Soares; Luís Antunes; Patrícia Redondo; Marina Borges; Ruben Hermans; Dony Patel; Fiona Grimson; Robin Munro; Carlos Chaib; Laure Lacoin; Melinda Daumont; John R Penrod; John C O'Donnell; Maria José Bento; Francisco Rocha Gonçalves

doi:10.2217/lmt-2020-0028

Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

Lung Cancer Manag. 2021 Feb 19;10(2):LMT46. doi: 10.2217/lmt-2020-0028.

Authors

Marta Soares¹, Luís Antunes², Patrícia Redondo³, Marina Borges³, Ruben Hermans⁴, Dony Patel⁴, Fiona Grimson⁴, Robin Munro⁴, Carlos Chaib⁵, Laure Lacoin^{6

7}, Melinda Daumont⁶, John R Penrod⁸, John C O'Donnell⁸, Maria José Bento^{2

9}, Francisco Rocha Gonçalves¹⁰

Affiliations

¹ Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal.
² Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal.
³ Outcomes Research Lab, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal.
⁴ Real World Solutions, IQVIA, London, N1 9JY, UK.
⁵ R&D Medical Affairs, Bristol Myers Squibb, 28050 Madrid, Spain.
⁶ Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, 1420 Braine-l'Alleud, Belgium.
⁷ Epi-Fit, Bordeaux, Nouvelle-Aquitaine 33000, France.
⁸ Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08540, USA.
⁹ Department of Population Studies, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4050-313 Porto, Portugal.
¹⁰ MEDCIDS, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.

Abstract

Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).

Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.

Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.

Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.

Keywords: non-small-cell lung cancer; non-squamous cell carcinoma; overall survival; real-world evidence; squamous cell carcinoma; stage I–IIIA; treatment patterns.